- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03683498
Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease (GVHD-TReG)
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study design is based on a phase I trial in Spanish.
A number of 16 patients will be included to assess the safety and maximum tolerated dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft versus host disease (cGVHD) patients who did not obtain complete remission under treatment with ruxolitinib.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Seville
-
Sevilla, Seville, Spain, 41013
- Hospital Universitario Virgen del Rocio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recipient of allogeneic hematopoietic stem cell transplantation.
- Participants must have steroid-refractory cGVHD and had obtained a partial response after at least 4 weeks of treatment with ruxolitinib.
- Steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD (Appendix D) despite the use of prednisone at ≥0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate glucocorticoids) without complete resolution of signs and symptoms.
- Stable dose of glucocorticoids for 4 weeks prior to enrolment
- No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for 4weeks prior to enrolment. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug
- No age limit. In the case of children participating in the study, the informed consent will be signed by a parents or legal guardians
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Participants must have adequate organ function
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Ongoing prednisone requirement >1 mg/kg/day (or equivalent).
- Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable).
- History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura.
- New immunosuppressive medication in the 4 weeks prior.
- Extra-corporeal Photopheresis or rituximab therapy in the 4 weeks prior.
- Post-transplant exposure to T-cell or Interleukin-2 targeted medication (e.g. alemtuzumab, basiliximab, denileukin diftitox) within 100 days prior.
- Donor lymphocyte infusion within 100 days prior.
- Active malignant relapse.
- Active uncontrolled infection.
- Organ transplant (allograft) recipient.
- HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the agents used after allogeneic hematopoietic stem cell transplant (HSCT). In addition, these individuals are at increased risk of lethal infections. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
- Individuals with active uncontrolled hepatitis B or C are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after hematopoietic stem cell transplant (HSCT).
- Other investigational drugs within 4 weeks prior to enrolment, unless cleared by the Principal Investigator.
- Pregnant women are excluded from this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Regulatory T-cell enriched infusion
Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below: Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg |
Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity and maximum tolerated dose
Time Frame: Up 12 weeks after infusion
|
To determine the maximum tolerated dose (MTD) and toxicity of Treg-enriched infusion among patients receiving ruxolitinib.
|
Up 12 weeks after infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantification of targeted cells of manufacturing Treg-enriched product meeting the targeted cell dose-level.
Time Frame: Before 24 hours to infusion up infusion day
|
Percentage of cells viability, negative gram stain/endotoxin, percentage of CD4+CD25+ cells and CD4+CD25+CD127- Treg in order to consider for the infusion.
|
Before 24 hours to infusion up infusion day
|
Clinical response of Treg-enriched infusion
Time Frame: Up 12 weeks after Treg infusion
|
Each participant should be assigned one of the following categories: 1) complete cGVHD response per NIH criteria, 2) partial cGVHD response per NIH criteria, 3) non-response (includes stable disease) per NIH criteria, 4) progressive cGVHD per NIH criteria, 5) malignant disease relapse, or 6) unknown (not assessable, insufficient data).
|
Up 12 weeks after Treg infusion
|
Immunologic effects through phenotypical evaluation
Time Frame: Up 12 weeks after Treg infusion
|
Phenotypical evaluation of T cell populations (CD4, CD8, Treg), B and NK cells nuclear cells of Treg-enriched infusion among patients receiving ruxolitinib.
|
Up 12 weeks after Treg infusion
|
Immunologic effects through immune globulins.
Time Frame: Up 12 weeks after Treg infusion
|
Quantitative immune globulins of Treg-enriched infusion among patients receiving ruxolitinib
|
Up 12 weeks after Treg infusion
|
Immunologic effects through plasma banking
Time Frame: Up 12 weeks after Treg infusion
|
Plasma banking of Treg-enriched infusion among patients receiving ruxolitinib
|
Up 12 weeks after Treg infusion
|
Immunologic effects through additional mononuclear cells.
Time Frame: Up 12 weeks after Treg infusion
|
Storage of additional mononuclear cells of Treg-enriched infusion among patients receiving ruxolitinib
|
Up 12 weeks after Treg infusion
|
Survival after one year of Treg infusion
Time Frame: 1 year after Treg infusion
|
Number of patients alive after one year of Treg infusion
|
1 year after Treg infusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: José Antonio Pérez-Simón, M.D. Ph.D., Department of Hematology, Hospital Universitario Virgen del Rocío, Sevilla.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GVHD-TReG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Graft vs Host Disease
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyCompleted
-
Shenzhen University General HospitalRecruitingGraft Vs Host DiseaseChina
-
Dana-Farber Cancer InstituteCompletedGraft vs Host Disease | Chronic Graft vs Host Disease | cGVHDUnited States
-
National Cancer Institute (NCI)TerminatedGraft vs Host Disease | Graft-Versus-Host Disease | Chronic Graft vs. Host DiseaseUnited States
-
St. Petersburg State Pavlov Medical UniversityMinistry of Health, Russian FederationCompleted
-
National Cancer Institute (NCI)Completed
-
Janssen Korea, Ltd., KoreaTerminatedChronic Graft vs Host DiseaseKorea, Republic of
-
Fundación Pública Andaluza para la gestión de la...RecruitingChronic Graft vs Host DiseaseSpain
-
Hospital Universitario Dr. Jose E. GonzalezRecruitingChronic Graft-versus-host-diseaseMexico
-
Shanghai General Hospital, Shanghai Jiao Tong University...Terminated
Clinical Trials on Regulatory T-cell enriched infusion
-
Fundación Pública Andaluza para la gestión de la...RecruitingChronic Graft vs Host DiseaseSpain
-
Massachusetts General HospitalDana-Farber Cancer Institute; University of RegensburgCompletedKidney Failure, Kidney TransplantUnited States
-
Mario ArpinatiEuropean CommissionRecruitingChronic Graft Versus Host DiseaseItaly
-
Assistance Publique - Hôpitaux de ParisPierre and Marie Curie University; Université Paris XIICompletedHematologic Neoplasms | RelapseFrance
-
Loma Linda UniversityRecruitingGraft Failure | Acute Rejection of Renal TransplantUnited States
-
Ain Shams UniversityNot yet recruitingType 1 Diabetes Mellitus | Lupus NephritisEgypt
-
Laura JohnstonNational Institutes of Health (NIH)CompletedGraft Versus Host Disease | Allogeneic Hematopoietic Cell Transplant RecipientUnited States
-
Talaris Therapeutics Inc.Duke UniversityNo longer availableMetachromatic LeukodystrophyUnited States
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Talaris Therapeutics Inc.Duke UniversityWithdrawnAnemia, Sickle Cell | Thalassemia | Beta-Thalassemia | Bone Marrow Failure Syndromes | Diamond-Blackfan Anemia | Alpha-Thalassemia | Complex and Transfusion-dependent HemoglobinopathiesUnited States